…for patient comfort.
H1 FY3/2026 Results
Date of Release: October 29, 2025
Earnings Call: October 30, 2025
Japan Lifeline Co., Ltd.TSE Prime Market Ticker 7575
Unauthorized copying prohibited.
Copyright © 2025 Japan Lifeline Co., Ltd. All rights reserved.
H1 FY3/2026 Results
Watch the H1 results (Eng.) presented by our AI CFO avatar here.
The video will be released 10:00 AM, Oct. 30, 2025 (JST)(Concurrent with the live earnings presentation).
Q&A Session
Appendix 1 Reference Materials Appendix 2 Investors Guide (Summary)
A fact sheet is available in PDF or excel on our website at https://www.japanlifeline.com/investors/ 2
H1 FY3/2026 Results
Q&A Session
Appendix 1 Reference Materials Appendix 2 Investors Guide (Summary)
A fact sheet is available in PDF or excel on our website at https://www.japanlifeline.com/investors/ 3
Highlights
(¥mn) | H1 FY3/2026 |
Net Sales | Record-High 29,285 + 4.6% YoY |
Operating Profit | Record-High 6,620 + 5.7% YoY |
Net Profit*1 | Record-High 4,774 + 7.7% YoY |
External
Factors
Net sales, OP, and NP reached record-highs for H1
(+) AF procedure volume +10% YoY (ー) PFA*2 impacts on select products
(ー) Official price revisions (2-month impact)*3
Internal Factors
(+) Strong core products*4 performance
(+) New therapeutic areas +38.4% YoY
(+) Partial recovery of bad debt (one-off factor)
4
*1 Net profit attributable to owners of the parent *2 Pulsed Field Ablation. *3 Official prices were revised in June 2024. Sales prices in April and May declined YoY. *4 The core products: (1) Intracardiac defibrillation catheter (BeeAT), (2) Femoral vein hemostatic device, (3) S-ICD, and (4) Frozen Elephant Trunk
Reimbursement prices are revised every two years; revision month changed to
June since 2024
Revision Month
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
CurreFY3/25
Old Price nt Price -->FY3/26
Current FY. No revision
FY3/27
New Price -->
In the H1 YoY comparison, a two-month period with price differences acts as a headwind to revenue and profit performance.
¥454,000
-->
¥391,000
(-13.9%)
¥3,120,000
-->
¥3,120,000
(no change)
*Core product
¥66,100
-->
¥64,000
(-3.2%)
¥214,000
-->
¥214,000
(no change)
*Core product
¥117,000
-->
¥110,000
(-6.0%)
¥1,430,000
-->
¥1,430,000
(no change)
*Core product
Pacemaker (type 4)
S-ICD (Main body)
EP Cath (Coronary Sinus Type)
Intracardiac Defibrillation Cath
Vascular Graft (Straight)
FET (4-branch Type)
Example: Previous revision (June 2024)
5
H1 net sales and each profit grew YoY, hitting record-highs
(¥mn except for per share amount)
H1 FY3/2025
H1 FY3/2026
Change
Change%
Comments
Net sales
27,985
Record 29,285
High
+ 1,299
+ 4.6
(+) Sales volume increased with more cases (+) New therapeutic areas expanded
Gross profit
16,963
17,557
+ 593
+ 3.5
(+) Sales volume increased with more cases
(ー) Price revision (2-mon. impact)
(ー) Product mix
%
60.6%
60.0%
(60bps)
SG&A
10,703
10,937
+ 234
+ 2.2
See next page
Operating profit
6,260
Record 6,620
High
+ 359
+ 5.7
See next page
%
22.4%
22.6%
+ 20bps
Net profit*1
4,435
Record 4,774
High
+ 339
+ 7.7
%
15.8%
16.3%
+ 50bps
Proprietary sales mix
57.6%
55.1%
(250bps)
Procured products expansion: neuro & hemostatic devices; Proprietary products decline including esophageal catheters*2
International sales mix
2.0%
2.6%
+ 60 bps
EPS (¥)
61.87
68.08
+ 6.21
+ 10.0
(+) Acquisition & cancellation of treasury stock (May 2024)
*1 Net profit attributable to owners of the parent *2 Proprietary product sales increased 0.1% YoY, while procured product sales increased 10.7% YoY 6
Core Products*1/New TAs offset PFA impact; profit rose on bad debt recovery
Core Products
Hemostatic device + 436
Defibrillation catheter(BeeAT) + 311
FET *² + 93
S-ICD + 72
New TAs
Neuro + 161
Gastro + 134
+ 913
+ 295
New TAs
Other products
PFA impact (617)
(Eso catheter & others)
Exports +38
Selling price Impact and other factors *³
Personnel (198)
R&D (192)
Sales-related (150)
Increase in SG&A expenses
(Excl. one-off)
YoY
＋ 359Up 5.7%
(¥mn)
6,260
Core Products
(563) (51) + 405
Reimbursement prices revised down
6,620
--> Impact: approx. (90)
in 2-month
Improvement in COGS, lower purchase prices
(639)
One-off factors
(Positive)
Sales volume Unit price
Bad Debt Related *⁴ +416
Misc. Income *⁵ (10)
H1 FY3/2025
Operating Profit
Sales/COGS-related factors
+593
SG&A-related factors
(234)
H1 FY3/2026
Operating Profit
*1 Highly competitive strategic focus products *2 Frozen Elephant Trunk *3 Main factors include changes in selling/cost prices, and impact from product disposal/valuation loss *4 Recorded ¥216mn provision for doubtful 7
accounts for one client in H1 FY3/2025. Reversed ¥199mn of this provision in H1 FY3/2026 due to partial debt recovery. *5 Misc. income related to inventory transfer following termination of Baylis product sales agreement
H1 FY3/2026 Progress on Initial Guidance
Revenue and profit progressed mostly in line with the initial guidance
(¥mn)
59,300
Net sales
59,300
100.0%
(¥mn)
12,900
Operating profit
12,900
(¥mn)
Vs. Full-year Guidance
51.3%
6,620
6,300
3,272
3M
6M
9M
12M
FY3/2026
9,350
Net profit
9,350
100.0%
44,475
Vs. Full-year Guidance
49.4%
29,285
29,300
14,616
3M
6M
9M
12M
FY3/2026
75.0%
9,675
7,013
75.0%
29,650
50.0%
6,450
4,675
50.0%
14,825
25.0%
3,225
2,338
25.0%
0 0.0% 0 0 0.0%
Vs. Full-year Guidance
51.1%
4,774
4,500
2,302
3M
6M
9M
12M
FY3/2026
ActualGuidanceActualGuidanceActualGuidance8
Our Product Categories
Cardiac Business Composition: 94%*1
CRM (Cardiac Rhythm Management)
23%
EP/Ablation
49%
Cardiovascular
22%
Implantable electric devices to treat arrhythmias
Stable
Medical tubes used in arrhythmia procedures
[Core Product]
Vascular grafts used in aortic surgeries
Core
Business
[Core Product] S-ICD
Intracardiac Defibrillation Catheter
[Core Product] Hemostatic Device
Business
[Core Product] Frozen Elephant Trunk
New Therapeutic Areas Composition: 6%*1
Neurovascular
Medical devices used to treat neurovascular diseases
3%
High
Gastrointestinal 3%
Medical devices used to treat digestive diseases
*1 Composition rates are actual results for FY3/2025
Aspiration Catheter
Embolic Coil
Growth Business
Bile-Duct Tube Stent 9
Our Business Model
Sales
Revenue tied to procedure volume
Number of procedures
Our market share
Official Prices
Wholesale price rate
Volume
Unit Price
--> National health insurance reimbursement prices (NHI)
Most of our products are single-use medical devices used in surgeries 10